“Before being diagnosed with COPD, I lived a dramatically wonderful life. As my disease has progressed, it’s become harder for me to do the things I never thought twice about,” shares Edna Shattuck, a Chronic Obstructive Pulmonary Disease (COPD) patient and retired nurse in Chevy Chase, MD. Edna is one of more than 15 million Americans diagnosed with COPD, the third leading cause of death in the United States and the second leading cause of disability.
At AstraZeneca, patients like Edna motivate us to push the boundaries of science to deliver life changing medicines. However, we recognize that solving today’s most pressing health challenges and delivering the best outcomes for patients will not come from medicines alone. This is why our corporate responsibility investments support organizations, programs and policies that advance patient and community health beyond the medicine by addressing unmet patient needs, driving health and science innovation and supporting the communities where we live and work.
This November, in recognition of COPD Awareness month, we highlight our commitment to advancing respiratory health beyond the medicine. The video below profiles COPD360: A Pathway to Cures, a program that AstraZeneca helped to found in 2014 with the COPD Foundation. COPD360 aims to speed COPD research progress by building the largest-ever registry of COPD clinical trial participants, and enables better outcomes for patients by connecting them to an online support community. With more than 2.5 million reached and 25,000 patients registered to date, COPD360 is benefitting respiratory patients nationwide.
Edna Shattuck, COPD patient, Dr. Byron Thomashow, a pulmonologist at Columbia University Medical Center, and Sara Latham, COO, COPD Foundation share their perspectives on COPD360 and the positive impact of this program.
AstraZeneca’s support for COPD360 is one of many corporate responsibility investments we are making to advance respiratory health beyond the medicine. As respiratory leaders, innovative partnerships across the entire respiratory health community are critical components of delivering on our strategy to help COPD patients breathe better.
The infographic below illustrates our full corporate responsibility approach, including the four bold goals we are addressing alongside our national partners.
Stay tuned for more in the AstraZeneca Gives Back series on the impact we’re having in the fields of oncology, cardiovascular and metabolic disease. Learn more about how we’re advancing patient and community health beyond the medicine by visiting the Sustainability section of our website.